Filing Overview
Tenaya Therapeutics, Inc. filed a Form 8-K dated December 22, 2021, under Item 5.02(d) to report the appointment of a new director.
Business Context and Reporting Period
Tenaya is a Delaware corporation headquartered in South San Francisco, California. Its common stock trades on Nasdaq under the symbol TNYA. The filing does not report quarterly or annual financial results.
Board and Governance Changes
- The Board increased its authorized size from nine to 10 directors.
- Karah Parschauer was appointed to the Board as a Class I director, with a term expiring at the 2022 annual meeting of stockholders.
- Ms. Parschauer was also appointed to the Audit Committee.
- The filing states that there were no arrangements or understandings related to her selection and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Compensation and Equity Award
- Annual cash retainer of $35,000 for service as a non-employee director.
- Additional annual cash retainer of $7,500 for Audit Committee service.
- Stock option with an approximate grant-date fair value of $320,000.
- The option vests monthly over 36 months, subject to continued service.
- The option accelerates in full upon a change in control, provided Ms. Parschauer remains a non-employee director through that date.
- Ms. Parschauer also entered into the Company’s standard indemnification agreement.
Financial Metrics and Outlook
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, financial guidance, or operating forecasts. The filing text does not provide clear values for these items.
Material Changes, Risks, and Unusual Items
The material event is the expansion of the Board and appointment of Ms. Parschauer to the Audit Committee. The principal economic item disclosed is the approximately $320,000 fair value of the new stock option and the associated director cash retainers. No new business risks, contingencies, litigation matters, or unusual financial items are disclosed.
Investor Verification Checklist
- Verify Ms. Parschauer’s background, qualifications, and expected contribution to the Board and Audit Committee.
- Review the Company’s non-employee director compensation policy and the terms of the stock option award.
- Confirm the Board’s revised size and director classification in subsequent proxy materials.
- Review Exhibit 99.1, the press release announcing the appointment.
- Use the Company’s periodic reports for financial performance, liquidity, cash runway, debt, and clinical-development updates, which are not included in this filing.